Advertisement
ABBV or LLY or REGN
Which Stock Would AI Choose? AbbVie (ABBV) vs. Eli Lilly (LLY) vs. Regeneron (REGN) Stock Comparison
Key Takeaways
- ABBV shares have gained around 9.7% over the recent month, supported by positive Phase 3 data for SKYRIZI in Crohn's disease and steady immunology portfolio growth.
- LLY experienced a roughly 7-8% pullback in recent weeks amid broader market corrections, despite strong long-term momentum from Mounjaro and Zepbound sales.
- REGN stock has shown modest stability with a slight monthly decline of under 1%, bolstered by Dupixent expansions and mixed analyst views on valuation.
- ABBV offers higher dividend yield and diversified revenue, while LLY leads in growth potential from obesity treatments.
- All three maintain strong positions in biotech/pharma, with year-to-date returns varying: ABBV up 0.6%, LLY down ~8%, and REGN down ~2%.
- Recent earnings beats across the board highlight resilience, though sector pressures like competition influence relative performance.
Introduction
AbbVie (ABBV), Eli Lilly (LLY), and Regeneron (REGN) represent key players in the biopharmaceutical sector, focusing on immunology, oncology, and innovative therapies. This stock comparison evaluates their recent market positioning, performance drivers, and relative strengths amid evolving healthcare demands. Traders seeking momentum plays and long-term investors eyeing stability in pharma stocks will find insights into growth trajectories, pipeline advancements, and valuation dynamics. With sector tailwinds from new approvals and challenges like patent dynamics, understanding these contrasts aids informed portfolio decisions in the current market environment.
ABBV Overview and Recent Performance
AbbVie (ABBV), a research-based biopharmaceutical firm headquartered in North Chicago, specializes in immunology, oncology, neuroscience, and aesthetics. Its portfolio features blockbusters like Skyrizi, Rinvoq, Imbruvica, and Botox. In recent market activity, ABBV shares have risen approximately 9.7% over the past month and 2.2% in the last week, trading around $230. Positive topline results from the Phase 3 AFFIRM study for SKYRIZI in Crohn's disease have bolstered investor sentiment, reinforcing its immunology leadership post-Humira erosion. Recent earnings showed adjusted EPS of $2.71, beating estimates, with 2026 guidance projecting revenues near $67 billion. These developments, alongside a 2.89% dividend yield, have driven outperformance versus broader indices, though oncology competition remains a watchpoint.
LLY Overview and Recent Performance
Eli Lilly (LLY), based in Indianapolis, develops pharmaceuticals in cardiometabolic, oncology, immunology, and neuroscience areas. Key products include Mounjaro, Zepbound, Verzenio, and Olumiant. Amid recent weeks, LLY shares have declined about 7.9% monthly and 2.8% weekly, hovering near $990, reflecting broader equity corrections and pricing concerns in diabetes/obesity markets. Despite this, robust Q4 results with 43% revenue growth to $19.3 billion, driven by blockbuster GLP-1 drugs, underscore strength. Analysts project 41% EPS growth for 2026, with the stock's high market cap over $880 billion signaling sustained leadership. Sentiment remains positive on pipeline expansion, though competition intensifies trade-offs in valuation sensitivity.
REGN Overview and Recent Performance
Regeneron Pharmaceuticals (REGN), a fully integrated biotech in Tarrytown, New York, targets eye diseases, inflammation, cancer, and rare conditions with products like Eylea, Dupixent, Libtayo, and Linvoseltamab. In recent trading, REGN has dipped slightly less than 1% monthly and 0.1% weekly, around $760, amid mixed analyst views. FDA expansions for Dupixent have enhanced market potential, while Q4 revenue beat estimates at $3.88 billion. Year-to-date down ~2%, the stock benefits from a broad pipeline in oncology and immunology, though stagnant sales concerns temper momentum. Trading at attractive multiples, it appeals for stability in volatile biotech exposure.
Trending AI Robots
Tickeron’s Trending AI Robots page curates the top-performing AI trading bots from hundreds available on the platform, which trade thousands of tickers across diverse strategies, timeframes, and market conditions. Only those excelling in current volatility—such as sector rotations in energy, semiconductors, and infrastructure—earn a spot, with stats like annualized returns up to 215%, win rates from 53% to 95%, profit factors reaching 25+, and low drawdowns (e.g., $1,500-$23,000 absolute). These bots employ AI/ML for technical/fundamental analysis on 5-60 minute intervals, handling 1-25 tickers per strategy, from leveraged ETFs like SOXL to multi-sector plays. Explore Trending AI Robots to identify bots suited to today’s pharma momentum and beyond.
Head-to-Head Comparison
ABBV, LLY, and REGN operate in overlapping biotech/pharma spaces but diverge in business models: ABBV's diversified immunology/aesthetics focus contrasts LLY's high-growth GLP-1 dominance and REGN's biotech emphasis on ophthalmology/oncology collaborations. Growth drivers include LLY's 41% projected EPS surge versus ABBV's steady 5-13% sales and REGN's pipeline catalysts like Dupixent. Recent momentum favors ABBV (9% monthly gain) over LLY (-8%) and REGN (-1%). Risk factors: LLY faces obesity competition, ABBV patent cliffs, REGN sales stagnation. LLY's premium valuation reflects growth, while ABBV and REGN offer value. Sentiment tilts toward LLY's scale, balanced by ABBV's yield.
Tickeron AI Verdict
Tickeron’s AI currently favors LLY for its superior trend consistency in GLP-1 catalysts, robust earnings growth outlook, and dominant market positioning amid obesity/diabetes demand. While ABBV shows short-term momentum and stability, and REGN undervaluation potential, LLY's relative strength in recent quarters suggests higher probability of outperformance, subject to sector volatility.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 2 FA rating(s) are green whileLLY’s FA Score has 2 green FA rating(s), and REGN’s FA Score reflects 2 green FA rating(s).
- ABBV’s FA Score: 2 green, 3 red.
- LLY’s FA Score: 2 green, 3 red.
- REGN’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 6 TA indicator(s) are bullish while LLY’s TA Score has 5 bullish TA indicator(s), and REGN’s TA Score reflects 2 bullish TA indicator(s).
- ABBV’s TA Score: 6 bullish, 4 bearish.
- LLY’s TA Score: 5 bullish, 3 bearish.
- REGN’s TA Score: 2 bullish, 7 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а +1.04% price change this week, while LLY (@Pharmaceuticals: Major) price change was -1.32% , and REGN (@Biotechnology) price fluctuated +0.40% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.75%. For the same industry, the average monthly price growth was +4.38%, and the average quarterly price growth was +7.68%.
The average weekly price growth across all stocks in the @Biotechnology industry was +6.61%. For the same industry, the average monthly price growth was +12.41%, and the average quarterly price growth was +11.94%.
Reported Earning Dates
ABBV is expected to report earnings on Apr 29, 2026.
LLY is expected to report earnings on Apr 30, 2026.
REGN is expected to report earnings on Apr 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.75% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
@Biotechnology (+6.61% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| ABBV | LLY | REGN | |
| Capitalization | 360B | 822B | 79.2B |
| EBITDA | 17.6B | 31.7B | 5.82B |
| Gain YTD | -7.305 | -13.595 | -2.793 |
| P/E Ratio | 85.95 | 40.08 | 18.07 |
| Revenue | 61.2B | 65.2B | 14.3B |
| Total Cash | N/A | 7.27B | 8.61B |
| Total Debt | 67.5B | 42.5B | 2.71B |
ABBV | LLY | REGN | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 35 Fair valued | 62 Fair valued | 3 Undervalued | |
PROFIT vs RISK RATING 1..100 | 14 | 20 | 75 | |
SMR RATING 1..100 | 1 | 13 | 54 | |
PRICE GROWTH RATING 1..100 | 55 | 55 | 26 | |
P/E GROWTH RATING 1..100 | 40 | 94 | 40 | |
SEASONALITY SCORE 1..100 | n/a | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
REGN's Valuation (3) in the Biotechnology industry is in the same range as ABBV (35) in the Pharmaceuticals Major industry, and is somewhat better than the same rating for LLY (62) in the Pharmaceuticals Major industry. This means that REGN's stock grew similarly to ABBV’s and somewhat faster than LLY’s over the last 12 months.
ABBV's Profit vs Risk Rating (14) in the Pharmaceuticals Major industry is in the same range as LLY (20) in the Pharmaceuticals Major industry, and is somewhat better than the same rating for REGN (75) in the Biotechnology industry. This means that ABBV's stock grew similarly to LLY’s and somewhat faster than REGN’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is in the same range as LLY (13) in the Pharmaceuticals Major industry, and is somewhat better than the same rating for REGN (54) in the Biotechnology industry. This means that ABBV's stock grew similarly to LLY’s and somewhat faster than REGN’s over the last 12 months.
REGN's Price Growth Rating (26) in the Biotechnology industry is in the same range as ABBV (55) in the Pharmaceuticals Major industry, and is in the same range as LLY (55) in the Pharmaceuticals Major industry. This means that REGN's stock grew similarly to ABBV’s and similarly to LLY’s over the last 12 months.
REGN's P/E Growth Rating (40) in the Biotechnology industry is in the same range as ABBV (40) in the Pharmaceuticals Major industry, and is somewhat better than the same rating for LLY (94) in the Pharmaceuticals Major industry. This means that REGN's stock grew similarly to ABBV’s and somewhat faster than LLY’s over the last 12 months.
| ABBV | LLY | REGN | |
|---|---|---|---|
| RSI ODDS (%) | 4 days ago 63% | 4 days ago 74% | N/A |
| Stochastic ODDS (%) | 4 days ago 58% | 4 days ago 70% | 4 days ago 75% |
| Momentum ODDS (%) | 4 days ago 65% | 4 days ago 61% | 4 days ago 52% |
| MACD ODDS (%) | 4 days ago 67% | 4 days ago 67% | 4 days ago 49% |
| TrendWeek ODDS (%) | 4 days ago 58% | 4 days ago 59% | 4 days ago 66% |
| TrendMonth ODDS (%) | 4 days ago 51% | 4 days ago 57% | 4 days ago 60% |
| Advances ODDS (%) | 12 days ago 57% | 12 days ago 71% | 20 days ago 64% |
| Declines ODDS (%) | 8 days ago 48% | 5 days ago 55% | 5 days ago 51% |
| BollingerBands ODDS (%) | 4 days ago 62% | 4 days ago 81% | 4 days ago 49% |
| Aroon ODDS (%) | 4 days ago 43% | 4 days ago 57% | 4 days ago 70% |
Advertisement
ABBV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with PFE. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then PFE could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | -0.29% | ||
| PFE - ABBV | 57% Loosely correlated | +1.25% | ||
| BMY - ABBV | 55% Loosely correlated | +2.05% | ||
| BIIB - ABBV | 51% Loosely correlated | +0.76% | ||
| AMGN - ABBV | 51% Loosely correlated | +1.69% | ||
| NVS - ABBV | 49% Loosely correlated | +1.50% | ||
More | ||||
LLY and
Correlation & Price change
A.I.dvisor indicates that over the last year, LLY has been loosely correlated with AZN. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if LLY jumps, then AZN could also see price increases.